派林生物
(000403)
| 流通市值：169.52亿 | | | 总市值：171.26亿 |
| 流通股本：9.41亿 | | | 总股本：9.50亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 986,481,770.22 | 374,649,641.98 | 2,654,684,638.93 | 1,890,265,336.27 |
| 营业收入 | 986,481,770.22 | 374,649,641.98 | 2,654,684,638.93 | 1,890,265,336.27 |
| 二、营业总成本 | 711,561,568.4 | 276,480,817.3 | 1,815,728,401.84 | 1,279,639,389.94 |
| 营业成本 | 516,643,833.95 | 194,591,295.34 | 1,350,398,183.86 | 935,384,603.19 |
| 税金及附加 | 9,109,303.92 | 4,170,200.87 | 22,065,908.63 | 15,460,100.12 |
| 销售费用 | 94,476,713.58 | 31,970,043.58 | 244,603,729.56 | 188,685,182.04 |
| 管理费用 | 92,875,459.96 | 45,749,811.48 | 192,654,925.98 | 131,080,445.38 |
| 研发费用 | 18,802,108.97 | 10,126,449.49 | 55,175,511.83 | 45,975,375.17 |
| 财务费用 | -20,345,851.98 | -10,126,983.46 | -49,169,858.02 | -36,946,315.96 |
| 其中:利息费用 | 7,035,425.59 | 3,525,951.41 | 10,674,708.92 | 7,684,012.88 |
| 其中:利息收入 | 27,501,762.99 | 13,705,087.74 | 60,267,046.58 | 44,948,849.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -6,227,157.72 | -2,357,007.78 | 6,380,660.77 | -10,592,156.39 |
| 加:投资收益 | 13,721,248.52 | 5,945,939.09 | 17,738,586.13 | 29,389,560.54 |
| 资产处置收益 | 785,805.25 | 15,810.9 | -118,875.57 | 58,070.35 |
| 资产减值损失(新) | -1,224,723.08 | - | -1,253,652.18 | - |
| 信用减值损失(新) | 991,885.31 | 5,786,270.57 | 4,652,743.66 | 2,858,186.89 |
| 其他收益 | 2,759,472.22 | 2,307,550.35 | 13,957,329.14 | 6,412,568.03 |
| 四、营业利润 | 285,726,732.32 | 109,867,387.81 | 880,313,029.04 | 638,752,175.75 |
| 加:营业外收入 | 12,240.3 | 9,881.49 | 639,614.75 | 105,896.52 |
| 减:营业外支出 | 16,808,850.66 | 6,514,926.73 | 28,174,586.14 | 19,311,603.61 |
| 五、利润总额 | 268,930,121.96 | 103,362,342.57 | 852,778,057.65 | 619,546,468.66 |
| 减:所得税费用 | 33,013,277.41 | 14,422,794.89 | 107,735,907.29 | 76,788,008.59 |
| 六、净利润 | 235,916,844.55 | 88,939,547.68 | 745,042,150.36 | 542,758,460.07 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 235,916,844.55 | 88,939,547.68 | 745,042,150.36 | 542,758,460.07 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 235,792,903 | 89,089,215.65 | 745,320,757.41 | 542,732,944.36 |
| 少数股东损益 | 123,941.55 | -149,667.97 | -278,607.05 | 25,515.71 |
| 扣除非经常损益后的净利润 | 214,668,744.31 | 76,456,078.54 | 683,191,198.14 | 498,235,715.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.25 | 0.12 | 1.02 | 0.74 |
| (二)稀释每股收益 | 0.25 | 0.12 | 1.02 | 0.74 |
| 八、其他综合收益 | -2,537.11 | -707.31 | 7,688.42 | -5,639.91 |
| 归属于母公司股东的其他综合收益 | -2,537.11 | -707.31 | 7,688.42 | -5,639.91 |
| 九、综合收益总额 | 235,914,307.44 | 88,938,840.37 | 745,049,838.78 | 542,752,820.16 |
| 归属于母公司股东的综合收益总额 | 235,790,365.89 | 89,088,508.34 | 745,328,445.83 | 542,727,304.45 |
| 归属于少数股东的综合收益总额 | 123,941.55 | -149,667.97 | -278,607.05 | 25,515.71 |
| 公告日期 | 2025-08-22 | 2025-04-24 | 2025-04-24 | 2024-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |